Victory Capital Management Inc. Has $19.98 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Victory Capital Management Inc. lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 690,398 shares of the specialty pharmaceutical company’s stock after selling 20,771 shares during the quarter. Victory Capital Management Inc.’s holdings in Supernus Pharmaceuticals were worth $19,980,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its stake in Supernus Pharmaceuticals by 96.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock worth $39,000 after buying an additional 687 shares in the last quarter. Covestor Ltd lifted its holdings in shares of Supernus Pharmaceuticals by 115.0% during the 3rd quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company’s stock worth $65,000 after acquiring an additional 1,257 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $262,000. Profund Advisors LLC increased its stake in Supernus Pharmaceuticals by 17.7% in the third quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company’s stock valued at $266,000 after acquiring an additional 1,454 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Supernus Pharmaceuticals by 28.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,949 shares of the specialty pharmaceutical company’s stock valued at $274,000 after purchasing an additional 2,203 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, Piper Sandler dropped their price objective on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, February 28th.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $30.21, for a total value of $151,050.00. Following the completion of the sale, the vice president now directly owns 8,570 shares in the company, valued at $258,899.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $30.21, for a total value of $151,050.00. Following the sale, the vice president now owns 8,570 shares in the company, valued at approximately $258,899.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Padmanabh P. Bhatt sold 14,491 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $35.31, for a total value of $511,677.21. Following the transaction, the vice president now owns 8,570 shares of the company’s stock, valued at $302,606.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,739 shares of company stock worth $1,227,433. Company insiders own 8.76% of the company’s stock.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $30.00 on Friday. The business’s 50-day moving average price is $31.76 and its 200-day moving average price is $28.92. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $38.08.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.39). Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The business had revenue of $164.30 million for the quarter, compared to analyst estimates of $155.03 million. During the same quarter in the prior year, the business earned $0.43 earnings per share. The firm’s quarterly revenue was down 1.8% on a year-over-year basis. Analysts predict that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.